Welcome to our dedicated page for Xenon Pharmaceuticals news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a pioneering biopharmaceutical company headquartered in Vancouver, British Columbia. Focused on neurology, Xenon leverages its proprietary discovery platform, termed 'extreme genetics', to develop innovative medications. The company’s approach involves studying families with severe phenotypes to identify single-gene defects, which offer insights into human biology and serve as potential drug targets.
Xenon’s development pipeline targets a range of neurological disorders, particularly epilepsy and depression. The flagship product, XEN1101, is a potent, selective potassium channel opener currently in various phases of clinical trials for epilepsy and major depressive disorder (MDD). Xenon has ongoing Phase 3 trials for XEN1101 in focal onset seizures (X-TOLE2, X-TOLE3) and primary generalized tonic-clonic seizures (X-ACKT). The drug has shown promising efficacy in reducing seizures and improving quality of life in long-term extension studies.
Additionally, Xenon is exploring XEN1101's potential in treating MDD, with a Phase 3 program expected to begin in 2024. Recent interim data from the X-NOVA Phase 2 trial revealed significant improvements in depression symptoms, supporting further development for this indication. Xenon’s pre-clinical work includes investigations into Nav1.1 and Nav1.7 potentiators for various neurological conditions.
Key developments include a partnership with Neurocrine Biosciences to develop XEN901 (NBI-921352) for epilepsy. Xenon's financial stability, robust clinical pipeline, and strategic collaborations position it for continued growth and innovation in neurology-focused therapeutics.
Recent Achievements:
- Strong presence at AES 2023 with multiple presentations on XEN1101
- Presented new data from the Phase 2b X-TOLE trial demonstrating significant seizure freedom rates
- Expanded open-label extension study collecting over 500 patient years of data
- Announced positive topline results from X-NOVA Phase 2 trial for MDD
- Ongoing collaboration with Icahn School of Medicine for additional MDD studies
For more updates and detailed information, visit the official website.
Xenon Pharmaceuticals presented new long-term data from its X-TOLE open-label extension (OLE) study of azetukalner for focal onset seizures at AES 2024. Key findings show that approximately one-third of patients on azetukalner for at least 36 months achieved seizure freedom for a year or longer, with sustained monthly seizure frequency reductions maintained at 85% at month 36.
The study demonstrated consistent tolerability and safety profile, with no new safety signals identified. Patient retention rates were 66%, 60%, and 52% at 12, 24, and 36 months respectively. Additional research presented highlighted significant mental health burdens in epilepsy patients and showed promising pre-clinical results for Nav1.1 potentiators in treating Dravet Syndrome.
Xenon Pharmaceuticals (XENE) announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (AES 2024), scheduled for December 6-10, 2024 in Los Angeles. The company will present five posters featuring new long-term 36-month data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures (FOS). The presentations will also cover mental health and comorbidity burdens of FOS, along with new pre-clinical data from the company's early-stage Nav1.1 program. The company will host a Scientific Exhibit and maintain booths at the event to showcase their clinical and research programs.
Xenon Pharmaceuticals (Nasdaq: XENE) has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Stifel 2024 Healthcare Conference on November 18 at 9:10 a.m. ET and the Jefferies London Healthcare Conference 2024 on November 20 at 1:30 PM GMT / 8:30 am ET.
Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead product, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications. Webcasts of the presentations will be available on Xenon's website investor section.
Xenon Pharmaceuticals reported Q3 2024 financial results and provided updates on its clinical programs. The company's lead drug azetukalner, a Kv7 potassium channel opener, is advancing in Phase 3 trials for epilepsy with topline data expected in H2 2025. The company had $803.3 million in cash as of September 30, 2024, expecting to fund operations into 2027. Q3 net loss was $62.8 million, up from $48.5 million in Q3 2023, primarily due to increased R&D expenses. The company is expanding its pipeline with multiple candidates advancing towards IND filings in 2025, including programs for Kv7, Nav1.7, and Nav1.1 targets.
Xenon Pharmaceuticals (Nasdaq: XENE) has announced it will report its third quarter 2024 financial results after U.S. market close on Tuesday, November 12, 2024. The company will host a conference call and webcast at 4:30 pm Eastern Time on the same day. Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced its participation in the upcoming BofA Securities 2024 CNS Therapeutics Virtual Conference on October 7, 2024. The company will present a fireside chat at 11:40 am Eastern Time, with a live webcast available on Xenon's website.
Xenon is dedicated to discovering, developing, and delivering life-changing therapeutics for patients with neurological and psychiatric disorders. Their novel product pipeline focuses on areas of high unmet medical need, including epilepsy and depression. The company's lead product, azetukalner, is a Kv7 channel opener in late-stage clinical development for multiple indications, representing the most advanced, clinically validated potassium channel modulator.
Xenon Pharmaceuticals (Nasdaq:XENE) presented three posters at the 15th European Epilepsy Congress showcasing long-term data for azetukalner, a novel Kv7 channel opener, in treating focal onset seizures (FOS). Key highlights include:
1. Patients in the X-TOLE open-label extension study showed >90% reduction in median monthly seizure frequency after 30 months.
2. Approximately 25% of patients on azetukalner for ≥2 years experienced ≥1 year of seizure freedom.
3. Quality of life improvements were reported in adults with FOS treated with azetukalner.
4. Xenon is conducting three Phase 3 trials for azetukalner in FOS and primary generalized tonic-clonic seizures (PGTCS).
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has appointed Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the senior executive team. Dr. Ronsheim, with 25 years of experience in pharmaceutical development and manufacturing, will lead Chemistry, Manufacturing and Controls (CMC), Program Management, and Quality Assurance. He will focus on preparing for the commercial launch of azetukalner, Xenon's lead Kv7 channel opener in late-stage clinical development for epilepsy and depression.
Dr. Ronsheim joins Xenon from Innoviva Specialty Therapeutics, where he served as President. His extensive experience includes leadership roles at Entasis Therapeutics, Merck/Cubist Pharmaceuticals, Enanta Pharmaceuticals, and Forest Laboratories. His appointment comes at a important time as Xenon advances its Phase 3 epilepsy and MDD programs and progresses its pre-clinical assets.
Xenon Pharmaceuticals (Nasdaq: XENE) reported Q2 2024 financial results, highlighting multiple clinical advancements and financial figures.
The phase 3 epilepsy program with azetukalner continues, anticipating topline data for X-TOLE2 in H2 2025. The MDD program is on track, with a Phase 3 study expected to initiate in H2 2024. Xenon is also progressing multiple Kv7 and Nav1.7 candidates, with IND filings expected in 2025.
Financially, the company reported cash and equivalents of $850.6 million as of June 30, 2024, down from $930.9 million at the end of 2023. Research and development expenses increased to $49.7 million, with a net loss of $57.9 million for Q2 2024, compared to a $47.5 million loss in Q2 2023.
Xenon remains financially poised to operate into 2027, bolstered by ongoing clinical trials and a robust pipeline of innovative treatments.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024. The company will host a conference call and webcast at 4:30 pm Eastern Time on the same day to discuss the results.
Xenon is dedicated to discovering, developing, and delivering life-changing therapeutics for patients with neurological and psychiatric disorders. Their lead product, Azetukalner, a Kv7 channel opener, is in late-stage clinical development for multiple indications, representing the most advanced, clinically validated potassium channel modulator in its class.
FAQ
What is the current stock price of Xenon Pharmaceuticals (XENE)?
What is the market cap of Xenon Pharmaceuticals (XENE)?
What does Xenon Pharmaceuticals specialize in?
What is the focus of Xenon’s proprietary discovery platform?
What is XEN1101?
What are the recent achievements of Xenon Pharmaceuticals?
Who are Xenon’s strategic partners?
What are Xenon’s key products in the pipeline?
What is the status of the XEN1101 epilepsy trials?
How can I contact Xenon Pharmaceuticals for investor information?
Where is Xenon Pharmaceuticals headquartered?